Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04354753
Other study ID # AU12
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 28, 2020
Est. completion date April 17, 2020

Study information

Verified date April 2020
Source Aarogyam UK
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

University of Warwick (Coventry, UK) and NTUU "Igor Sikorsky" Kyiv Polytechnic Institute (Kyiv, Ukraine), together with ClickMedix LLC, have developed an app and a chatbot "AiM COVID" for efficient monitoring and mitigation of COVID-19. These products are available for free download on computers and mobile phones. These can be used by a wide range of users from various sectors - patients and people living with them, doctors, nurses, specialists, community health workers, hospitals, clinics, hospital IT staff, MHFA, and insurance companies.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date April 17, 2020
Est. primary completion date April 14, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Participants 18 and above

- living in UK

- reported with or without symptoms from February 28 to March 28 with community support groups

Exclusion Criteria:

- below 18 years old

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No Intervention
No intervention

Locations

Country Name City State
United Kingdom Aarogyam (UK) Leicester

Sponsors (4)

Lead Sponsor Collaborator
Aarogyam UK ClickMedix LLC, Igor Sikorsky Kyiv Polytechnic Institute, University of Warwick

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Physical symptoms Self reported physical symptoms 1day
Primary Contact History Contact with suspected, confirmed or ill person 14 days
Primary Travel History Travel to or from overseas 14 days
Secondary Fever Self reported body temperature 1 day
Secondary Headache Self reported headache using yes/no 1 day
Secondary Soar Throat Self reported soar throat using yes/no 1 day
Secondary Runny nose Self reported runny nose using yes/no 1 day
Secondary Cough Self reported cough using yes/no 1 day
Secondary Shortness of breath Self reported shortness of breath symptoms using yes/no 1 day
Secondary Nausea Self reported nausea using yes/no 1 day
Secondary Vomiting Self reported vomiting using yes/no 1 day
Secondary Muscle pain Self reported muscle pain using yes/no 1 day
Secondary Joint pain Self reported joint pain using yes/no 1 day
Secondary Diarrhoea Self reported Diarrhoea using yes/no 1 day
Secondary Other Self reported other symptoms using yes/no 1 day
Secondary Hospitalisation history Self reported hospitalisation using yes/no 1 day
Secondary Co-morbid conditions Self reported co-morbid conditions using checked box 1 day
See also
  Status Clinical Trial Phase
Completed NCT04333732 - CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION Phase 3
Completed NCT04357457 - Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia Phase 3
Terminated NCT04435795 - Inhaled Ciclesonide for Outpatients With COVID19 Phase 2/Phase 3
Completed NCT04357444 - Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19 Phase 2
Completed NCT04357834 - WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Not yet recruiting NCT05052320 - Audiological Assessment of Recovered Covid 19 Subjects.
Withdrawn NCT04426344 - Core Warming of COVID-19 Patients N/A
Recruiting NCT05595031 - Evaluation of the Clinical Impact of Corticosteroid Duration on SARS-CoV-2 (COVID-19 WHO)
Terminated NCT04371978 - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Phase 3
Terminated NCT04401410 - Anti-SARS Cov-2 T Cell Infusions for COVID 19 Phase 1
Completed NCT04445337 - Stellate Ganglion Blockade in COVID-19 Positive Patients N/A
Active, not recruiting NCT04374487 - Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications Phase 2
Completed NCT04403243 - COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19 Phase 2
Completed NCT04375644 - Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT)
Completed NCT04394078 - Impact of COVID-19 Pandemic on Depression and Quality of Life
Recruiting NCT04407923 - Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment
Withdrawn NCT04519411 - Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure N/A
Completed NCT04426305 - Community Health Workers Against COVID19 N/A
Recruiting NCT04492514 - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation Phase 2
Completed NCT04399980 - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Phase 2